The estimated Net Worth of Richard Friesner is at least $52.7 Milión dollars as of 11 March 2021. Dr Friesner owns over 32,000 units of Schrodinger stock worth over $14,301,557 and over the last 5 years he sold SDGR stock worth over $37,956,000. In addition, he makes $399,354 as Co-Founder a Scientific Advisory Chairman and Director at Schrodinger.
Dr has made over 3 trades of the Schrodinger stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 32,000 units of SDGR stock worth $2,572,480 on 11 March 2021.
The largest trade he's ever made was selling 500,000 units of Schrodinger stock on 17 August 2020 worth over $31,020,000. On average, Dr trades about 74,500 units every 26 days since 2020. As of 11 March 2021 he still owns at least 694,925 units of Schrodinger stock.
You can see the complete history of Dr Friesner stock trades at the bottom of the page.
Dr. Richard A. Friesner is the Co-Founder, Scientific Advisory Chairman and Director at Schrodinger.
As the Co-Founder a Scientific Advisory Chairman and Director of Schrodinger, the total compensation of Dr Friesner at Schrodinger is $399,354. There are 6 executives at Schrodinger getting paid more, with Dr. Ramy Farid Ph.D. having the highest compensation of $1,010,921.
Dr Friesner is 68, he's been the Co-Founder a Scientific Advisory Chairman and Director of Schrodinger since . There are no older and 22 younger executives at Schrodinger.
Richard's mailing address filed with the SEC is C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK, NY, 10036.
Over the last 5 years, insiders at Schrodinger have traded over $1,009,056,149 worth of Schrodinger stock and bought 838,235 units worth $14,249,995 . The most active insiders traders include & Melinda Gates Foundation ..., David E Schrodinger Equity ... a Michael Lynton. On average, Schrodinger executives and independent directors trade stock every 10 days with the average trade being worth of $2,459,207. The most recent stock trade was executed by Kenneth Patrick Lorton on 6 March 2024, trading 5,574 units of SDGR stock currently worth $24,191.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrodinger executives and other stock owners filed with the SEC include: